Traders should view this as a strong validation of Certara's technology platform, likely to enhance commercial credibility and drive adoption across biopharma clients. Monitor for follow-on announcements regarding new client engagements or expanded use of Simcyp in other NDAs.
Price Chart
Executive Summary
Certara announced that its Simcyp® Simulator was used to support the FDA's acceptance of PBPK modeling in lieu of clinical studies for the approval of asciminib (Scemblix®), a first-in-class treatment for Chronic Myeloid Leukemia. This marks a significant regulatory validation of Certara's model-informed drug development technology, highlighting its ability to replace at least ten clinical pharmacology studies and streamline the NDA process.
Key Facts
- FDA accepted PBPK modeling via Certara's Simcyp Simulator in lieu of clinical studies for asciminib (Scemblix®) NDA approval.
- Modeling replaced at least ten dedicated clinical pharmacology studies.
- Asciminib is a first-in-class allosteric inhibitor for Chronic Myeloid Leukemia (CML).
- Simcyp's modeling supported dosing regimens and drug interaction profiles across diverse populations.
- Novartis, a Simcyp Consortium member, led the modeling work in collaboration with Certara.
Financial Impact
Significant long-term revenue potential as regulatory acceptance strengthens demand for Certara’s biosimulation tools; validation could lead to broader adoption and expanded contracts.
Risk Factors
- Revenue impact may be delayed as adoption cycles in biopharma are long.
- Success depends on continued regulatory acceptance beyond this single case.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3248265 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 16, 2026 6w ago | Institutional Cluster | $8.00 $8.40 | ▲ +5.00% | ▲ +6.98% | $9.36 (+17.00%) |
Aug 4, 2026 8w ago | 8-K | $7.80 $8.10 | ▲ +3.85% | ▲ +5.08% | $9.36 (+20.00%) |
Jul 15, 2026 11w ago | Press Release | $7.28 $8.15 | ▲ +11.95% | ▲ +8.33% | $9.36 (+28.57%) |
Jun 11, 2026 16w ago | Institutional Cluster | $5.27 $6.79 | ▼ −28.84% | ▼ −26.95% | $9.36 (−77.61%) |
May 11, 2026 20w ago | 8-K | $5.13 $5.18 | ▼ −0.97% | ▼ −1.28% | $9.36 (−82.46%) |
May 11, 2026 20w ago | Press Release | $5.13 $5.18 | ▼ −0.97% | ▼ −1.28% | $9.36 (−82.46%) |
Apr 22, 2026 23w ago | 8-K / PRESS-RELEASE | $6.38 $4.59 | ▼ −28.06% | ▼ −31.22% | $9.36 (+46.71%) |
Apr 3, 2026 26w ago | DEFA14A | $5.46 $6.19 | ▲ +13.37% | ▲ +4.39% | $9.36 (+71.43%) |
Mar 30, 2026 26w ago | Court Ruling | $5.68 $6.14 | ▲ +8.10% | ▼ −4.50% | $9.36 (+64.79%) |
Mar 3, 2026 30w ago | Press Release | $7.24 $5.70 | ▼ −21.27% | ▼ −16.87% | $9.36 (+29.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access